Cohen Fred E 4

What Happened
Fred E. Cohen, a director of Kyverna Therapeutics, was granted compensation awards on May 27, 2026: 5,093 shares of common stock and 20,582 derivative shares (an award/option). Both grants show an acquisition price of $0.00 (total cash value reported $0), indicating these are company awards rather than open‑market purchases.

Key Details

• Transaction date: May 27, 2026; Form 4 filed May 29, 2026 (timely filing).
• Grants: 5,093 common shares (award) and 20,582 derivative shares (option/derivative) at $0.00.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Footnotes:
  • F1: The 5,093 award is a restricted stock unit that vests in full on the earlier of May 27, 2027 or immediately before the issuer's 2027 annual meeting, subject to continuous service.
  • F2: The 20,582 derivative shares are subject to an option that will be fully vested and exercisable on the earlier of May 27, 2027 or immediately before the 2027 annual meeting, subject to continuous service.
  • F3: Notes certain shares held by Vida Ventures, LLC and clarifies potential shared voting/dispositive power among managers (they disclaim beneficial ownership except for any pecuniary interest).
• No indication of a 10b5-1 plan, tax‑withholding sale, or immediate sale of shares in this filing.

Context
These entries are compensation awards (RSUs/options) that vest in the future if the director remains in service; they are not purchases that directly signal personal bullishness. The derivative award will become exercisable upon vesting per the footnote. For retail investors, awarded shares are common for retaining/compensating insiders and do not by themselves indicate intent to buy or sell stock.